Abbott to Pay $175 Million in Interest on Humira Patent Case Award

Abbott Laboratories will end up paying Centocor Ortho Biotech more than $1.8 billion for infringing the company’s Humira patent, including more than $175 million in interest. The U.S. District Court for the Eastern District of Texas added the interest to the jury award Centocor is due in the dispute in which it alleged that Abbott willfully infringed its patent by manufacturing Humira (adalimumab), a tumor necrosis factor alpha blocker.
Drug Industry Daily